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Currently, neuropsychological impairment among HIV+ patients on antiretroviral therapy leads to a reduction in the
quality of life and it is an important challenge due to the high prevalence of HIV-associated neurocognitive disorders
and its concomitant consequences in relation to morbidity and mortality- including those HIV+ patients with adequate
immunological and virological status. The fact that the virus is established in CNS in the early stages and its persistence
within the CNS can help us to understand HIV-related brain injury even when highly active antiretroviral therapy is
effective. The rising interest in HIV associated neurocognitive disorders has let to development new diagnostic tools,
improvement of the neuropsychological tests, and the use of new biomarkers and new neuroimaging techniques that
can help the diagnosis. Standardization and homogenization of neurocognitive tests as well as normalizing and
simplification of easily accessible tools that can identify patients with increased risk of cognitive impairment represent
an urgent requirement. Future efforts should also focus on diagnostic keys and searching for useful strategies in order
to decrease HIV neurotoxicity within the CNS.
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Disruption of neurocognitive functioning is one of the
most frequent complications in patients infected with HIV
nowadays. This is a common reason for consultation of
HIV patients and it negatively affects their quality of life,
treatment adherence and life span. Since the introduction
of Highly Active Antiretroviral Therapy (HAART) the
spectrum of HIV-associated neurocognitive disorders
(HAND) has been radically changed with a significant re-
duction in dementia but with a high prevalence of asymp-
tomatic and mild neurocognitive impairments. Currently,
in clinical practice, patients with HIV are still admitted to
the clinic for memory, concentration or planification
problems even when virology is under control. These usu-
ally begin with subtle changes but it can lead to more se-
vere forms of neurocognitive impairment. The aim of this
review is to describe the different types of neurocognitive
disorders, possible mechanisms of development, epidemi-
ology and risk factors in HIV patients, as well as the clin-
ical approach and current treatment of HAND.* Correspondence: msanmarti@mutuaterrassa.cat
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Before 1991, there was only one kind of neurocognitive
disorder defined, the HIV-associated dementia (HAD),
which was known as the complex AIDS-Dementia. It af-
fected patients with severe immune-depression causing se-
vere impairment of cognition, frequently accompanied by
motor and behavioural alterations. More recently, the
American Academy of Neurology proposed a new classifi-
cation by defining two levels of neurological impairment
in patients with HIV: the classical HAD and the minor
cognitive motor disorder (MCMD) representing patients
that did not meet dementia criteria but complained of
slight impairments that interfered with their daily life [1].
In 2007, a further revised classification system of HAND
was introduced which is thought to be more precise and
sensitive (Frascati Criteria). It describes, beside HAD,
other two neurocognitive disorders: Mild Neurocognitive
disorder (MND) and Asymptomatic Neurocognitive im-
pairment (ANI). MND is defined as mild to moderate im-
pairment within at least two cognitive areas with at least
mild impairment of daily function. ANI is defined as any
degree of neuropsychological testing impairment in at
least two cognitive domains but without causing an ob-
servable functional impairment [2] (See the “Classification
of HAND” Section). Finally, cognitive neuropsychologyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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across the domains of executive functions, motor skills,
speeded information processing, episodic memory, atten-
tion/working memory, language, and visuoperception [3].
Classification of HIV-associated neurocognitive disorders
Asymptomatic neurocognitive impairment (ANI)
1. No evidence of preexisting cause. Cognitive
impairment must be attributable to HIV and no
other etiology (e.g. dementia, delirium).
2. The cognitive impairment does not interfere with
activities of daily living.
3. Involves at least two cognitive areas (memory,
attention, language, processing speed, sensory-
perceptual, motor skills) documented by perform-
ance of > 1 standard deviation below the mean of
standardized neuropsychological testing.
Mild neurocognitive disorder (MND)
1. No evidence of preexisting cause. Cognitive
impairment must be attributable to HIV and no
other etiology (e.g. dementia, delirium).
2. At least mild interference in > 1 activities of daily
living including mental acuity, inefficiency at work,
homemaking or social functioning.
HIV-Associated dementia (HAD)
1. No evidence of another preexisting cause for
dementia (i.e. CNS infections, CNS neoplasm,
cerebrovascular disease).
2. Marked interference in activities of daily living.
3. Marked cognitive impairment involving at least two
cognitive domains by performance of > two
standard deviation below the mean of standarized
neuropsychological tests, especially in learning of
new information, slowed information processing and
defective attention or concentration.
Neuropathogenesis
The reason for neurocognitive disorders in HIV-patients is
still unclear. It is well known that the central nervous sys-
tem (CNS) is one of the target organs where HIV can
be detected soon after primary infection. Early neuro-
invasion is characterized by measurable markers of CSF
inflammation (eg, neopterin level) and by brain parenchy-
mal inflammation detected by magnetic resonance spec-
troscopy (MRS), although changes in neurocognitive
functioning are seen more clearly in advanced stages [2,4].
HIV enters the brain carried within migrating monocytes
and lymphocytes that cross the blood brain barrier (BBB)
and possibly CD4+ T lymphocytes that use the brain as a
reservoir for viral replication. After crossing the BBB, HIV
infected monocytes become active perivascular macro-
phages being able to produce HIV within the CNS, release
free virions and facilitate infection of microglial cells [5].Both cells types allow HIV replication concomitant with ex-
pression of neurotoxic molecules- thought to be the ones in-
volved in the pathogenesis of HAND [6] (eg. soluble
immune mediators). Astrocytes may also harbour HIV and
contribute to HIV-related brain disease through mechanisms
of astrogliosis induced by local chemokines and cytokines
leading to increased BBB permeability and consequently,
monocyte and lymphocyte migration. Neurons are not pro-
ductively infected.
Autopsy studies of AIDS patients with HAD shows
characteristic white matter changes and demyelination,
microglial nodules, multinucleated giant cells and perivas-
cular infiltrates [7]. A variety of proteins encoded by the
viral genome were identified as neurotoxic agents, includ-
ing gp120, the virus’s envelope protein, and transactivator
of transcription (Tat). Gp120 is necessary for infectivity,
but also interacts with host cellular receptors to alter glu-
tamate pathway signaling and induce cytokine production
that can injure neurons and affect the activation state of
microglia and astrocytes.
Tat protein which is produced by infected astrocytes [8]
has both neurotoxic and proinflammatory features. In sev-
eral studies where Tat-expressing astrocytes were injected
into the rat dentate gyrus it caused dendritic loss and neur-
onal cell death [9]. Furthermore, it is known that the virus is
not evenly distributed in the CNS. Different areas of the
brain are more susceptible to HIV due to the presence of in-
dividual viral genetic conditions and characteristics of the
host [10]. The regions in which HIV is most prevalent are
basal ganglia and the hippocampus, and to a lesser extent in
the cortex and cerebellar grey matter of the mid-frontal cor-
tex. These findings correspond with neuropsychological im-
pairment of the fronto-subcortical-region and dysfunction,
corresponding to frontal and subcortical areas [11]. Patients
infected with HIV frequently have co-morbid conditions
that may contribute to or amplify the pathogenicity of HIV,
thus having an important role in the development of neuro-
cognitive impairment (e.g. drug abuse and alcohol or infec-
tion with viral co-pathogens such as hepatitis C virus) [12].
Other factors that may contribute to HAND are the pro-
longed survival of HIV-infected patients, thereby extending
the brain’s exposure to HIV virions and proteins, the use of
increasingly toxic combinations of poorly penetrating drugs
in highly antiretroviral-experienced AIDS patients, and se-
lection of more virulent HIV strains with higher replica-
tion rates and greater virulence in neural tissues. Eden
and colleagues found that a substantial number of pa-
tients still show signs of macrophage/microglia activa-
tion even after 4 years of viral suppression with HAART
[13]. All these factors converge in producing damage to
dendrites and synapses leading to the disruption of the
highly integrated functioning of neural systems that is
required to process information, leading to HIV-
associated neurocognitive disorders.
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Several studies demonstrated that neurocognitive deficits
are more common in HIV+ patients than the HIV- popu-
lation, and these deficits were independent of either ART,
or disease state [14,15]. However, one recent study dem-
onstrated similar rates of cognitive impairment between a
subgroup of HIV+ patients, with a high CD4 level and
HIV viral suppression as compared with HIV- controls
[16]. A high prevalence of HIV-associated neurocognitive
disorders (HAND) is associated with a change in the pat-
tern of HAND and with an increased prevalence of mild
disease vs dementia [17,18]. Before the introduction of
HAART, the HIV-associated neurocognitive impairment
was categorized as AIDS-dementia complex, HIV enceph-
alitis or encephalopathy, with an estimated prevalence of
16% in patients with a diagnosis of AIDS [19]. However, in
the post-HAART era, the prevalence of dementia is esti-
mated to be less than 5% [17,20]. In contrast, it appears
that mild cognitive disorders are very common despite
treatment [17].
The prevalence of HAND is estimated in approximately
40-50% of all cases. Mild neurocognitive disorder (MND)
and Asymptomatic Neurocognitive Impairment (ANI) are
now more common than HAD. In a cross-sectional study
conducted in Switzerland, there was a prevalence of
HAND in 85% of patients with evidence of cognitive de-
cline, and 64% among those who did not demonstrate any
deterioration. In the first group, 24% had ANI, 52% MND
and 8% HAD, while in the second group 60% had ANI, 4%
MND and 0% HAD. Subclinical alterations that do not
affect the functionality of the patients or alter their daily
lives are the most frequent in both groups [17]. In a cross-
sectional study conducted on 1555 HIV infected patients
the CNS HIV Anti-Retroviral Therapy Effects Research
(CHARTER) found that 52% had HAND, of which 33%
had ANI, 12% MND and 2% HAD. The prevalence of im-
pairments correlated with the number of patient comor-
bidities [20]. Another study showed a 48% rate of
occurrence of cognitive decline in HIV-infected patients
[21], whilst the Aquitaine cohort found a prevalence of
58.5% TNAVs, 20.8% ANI, 31% MND, and 6.7% HAD
[18]. In Spain, a very recent multicenter study conducted
by questionnaire, found that 50% of the HIV+ population
complained of cognitive impairments. A high proportion
of them (72.1%) believed that their cognitive impairments
interfered with daily life activity [22].
Progression and implication
The real clinical relevance of ANI is not clear. It does not
interfere with daily life and in addition, it is not proven
that ANI patients are at increased risk of progression to
more advanced stages of deterioration. Moreover, there
are no satisfactory biomarkers or clinical prognostic/diag-
nostic indicators associated with this subgroup of patientsthat can determine evolution and end-point. The CHAR-
TER study reported preliminary results of monitoring at
18 and 42 months. The proportion of patients with wors-
ening neurocognitive function according to their basal
HAND classification was different in each group (ANI-
23%, MND-30%, not TNAV-13%), however there was no
statistically significant difference in mean decline in neu-
rocognitive function between ANI and MND groups [23].
From a prospective cohort, ACTG Longitudinal Linked
Randomized Trials (ALLRT) of 1160 patients from clinical
trials, 921 were examined using neuropsychological tests,
and were subsequently followed for 48 weeks. The preva-
lence of HAND was 39% at inclusion, of them 44% im-
proved after one year. In contrast, of those patiens without
HAND, 21% developed worse cognitive function [24].
Risk factors
The risk factors associated with neurocognitive disorders
are not well established in the post HAART era. They may
include host factors (e.g. genetic predisposition, metabolic
disorders, cardiovascular risk factor or aging), HIV-related
factors (AIDS, immune activation, drug resistance) and co-
morbidities such as hepatitis C virus co-infection or depres-
sion. Poor immunological status, reflected by lower nadir
CD4 cell count, has been associated with neurocognitive
impairment before and after HAART [20,24,25]. However,
other studies did not find this association with the CD4
levels [17,18,26]. The correlation with virological status is
even less clear in the HAART era [17,18,26]. Older age was
associated with neurocognitive impairment [18,21,25] and
HAD [27]. Valcour and collaborators [27] found about 3-
fold increased risk of HAD in patient >50 years compared
with those between 20 to 39 years old, independently of
other factors. Harezlak and co-workers found an associ-
ation between age and markers of brain injury in HIV in-
fected patients as compared with those being HIV negative
[21]. However, in other studies there was not a higher age-
related impairment of neuropsychological function between
HIV+ and HIV- populations [28]. Comorbidities, such as
coinfection with hepatitis C virus (HCV), were found to
be a risk factor for the presence of HAND [25,29] that
could be explained by an independent neurotoxic effect of
HCV. Other comorbidities as obesity and diabetes were
associated with neurocognitive impairment, especially in
older patients [30].
Data on neuropsychiatric symptoms in coinfected per-
sons are inconclusive at this time. With regard of depres-
sion was the most common disorder by far, reaching rates
of 71% and 62% for past depression in coinfected and
HIV-infected persons, respectively, and 42% for current
rates in both groups. Past dysthymia, past posttraumatic
stress disorder, and childhood conduct disorder were the
next most prevalent, with rates for each ranging between
16% and 19% in both groups [31]. Other cardiovascular
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tive performance [18,32]. Host genetic factors such as apo-
lipoprotein E4 have been suggested as possible risk factors
for neurocognitive impairment [33]. Whilst in the general
population, sub-groups with the ApoE4 allele have a worse
prognosis for neurodegeneration [34], this risk is less clear
in the HIV+ population [35,36].
Clinical features
The landmark of neuropsychological impairment in pa-
tients infected with HIV has changed in recent years par-
ticularly after the introduction of HAART. Currently, most
patients with alterations in neurocognitive tests have no
evident symptoms or dysfunction in their daily lives (ANI).
It has been demonstrated that the neurocognitive impair-
ment in early stages of infection shows a subcortical pattern
and in more advanced stages implicates more cortical areas.
The main cognitive complaints of the patients with mild
cognitive dysfunction involve subtle changes in working
memory and attention, speed of informational processing,
executive functioning (including organizing, planning and
problem-solving) or difficulties in verbal fluency. Motor
symptoms are less common but can include leg weakness,
tremor or unsteady gait. HAD, however, is often character-
ized by a progressing subcortical dementia with classically
severe memory loss and altered executive function. More
advanced stages also show aphasia, agnosia and apraxia,
that are more typical of cortical dementias such as Alzhei-
mer’s disease. Other neurobehavioral disturbances resulting
from HIV-mediated neural damage include emotional and
other behavioural disturbances (e.g. depression, anxiety,
sleep disorders, mania and psychosis) [37].
Diagnosis
Any individual with HIV infection could be at risk of
developing HAND [38]. Therefore, the need for a sys-
tematic study of cognitive HIV infected individuals
seems increasingly evident. Although many different
studies assessing neurocognitive impairment in HIV in-
fection have been published, a standard approach to op-
timally assessing neuropsychological deficits does not
currently exist. Multiple clinical tests are available for
use in order to evaluate neurocognitive function al-
though there is currently no single and universal neuro-
psychological battery to assess specifically people with
HIV. Evaluation of the different cognitive functions re-
quires a concerted effort (2–4 hours) with the need for
expert staff specialized in clinical neuropsychology who
has to evaluate at least five of the following cognitive
abilities: verbal/language, attention/working memory,
abstraction/executive functioning, learning/recall, speed
of informational processing, and sensory-perceptual
and motor skills. This has led to the need for screening
instruments that, although maybe useful in the initialscreening, are insufficient to make a good neuropsycho-
logical diagnosis within clinics. The classic tests-mini-
mental state examination (MMSE) or Montreal cognitive
assessment (MoCA) are not sufficiently sensitive to screen
for HAND unless the patients are symptomatic [39].
There are specific screening instruments for assessing
the HIV Dementia Scale HAND (HDS) [40], The Inter-
national HIV Dementia Scale (IHDS) [41] or the Mon-
treal cognitive assessment (MoCA) [42]. All these tests
can be performed in less than ten minutes. Other tests
often used in conjunction with these include the Brief
Neurocognitive Screen (BNC) [43], screening battery of
HNRC [44], computed COGSTATE [45] or Neu Screen-
ing [46]. The diagnosis of HAND is confirmed by the
clinical detection of cognitive impairment through
neuropsychological testing and the evidence of neuro-
cognitive impairment. Cognitive impairment must be at-
tributable to HIV after excluding other causes that can
justify the disorder (Figure 1).
Differential diagnosis
The differential diagnosis of neurocognitive disorders as-
sociated with HIV infections presents with two difficulties:
1) to discard all the pathologies that can lead to neurocog-
nitive disorders in the general population, associated or
not with HIV; 2) to determine the degree of contribution
of certain comorbidities associated with HIV infection, be-
fore attributing neurological damage to HIV itself. This
group may act as true comorbidity confounders while
attempting to diagnose a neurocognitive disorder in pa-
tients associated with HIV infection [47]. When the pres-
ence of neurocognitive impairment is suspected, an
exhaustive study has to be done in order to detect other
potential causes of neurocognitive impairment, including
laboratory testing of vitamin B12, folate level, TSH, syph-
ilis, hepatitis C, glucose and vitamin B1 as well as screen-
ing for dyslipidaemia. Sometimes, it is necessary to
examine CFS especially when there are other signs of CNS
infection, fever, CD4 cell counts below 200 cells/mm3 or
positive serology for syphilis.
Other testing should include screening for major depres-
sion and anxiety, prescription of psycho-pharmacologic
treatments and identification of self-abuse of other sub-
stances. Frequently, patients present other comorbidities
such as psychiatric illness, vascular cerebral disease, oppor-
tunistic infections, alcohol and drugs abuse. All these fac-
tors can cause neurocognitive disorders or contribute to
HAND progression [2]. It is a requirement to know the real
impact of comorbidities in order to find new prevention
and treatment strategies.
There is a growing interest in finding biomarkers that are
sensitive and specific for HAND. One of the most reliable
biomarker currently used for monitoring disease progres-
sion and HAART effectiveness is CD4 cell count. Counts
Specific 
intervention in 
comorbidities
Comorbidities
(coinfection HCV, emotional
and other behavioural
disturbances, drug abuse, 
alcohol, neurologic disease)
Abnormal Consider other causes of
neurocognitive impairment
(LP is recommended)
HAND
(LP is recomended)
6 months
No
Dementia blood test.
Neuroimaging
Neuropsychological 
tests
Yes
Normal Abnormal
Normal
HIV-PATIENT
Cognitive complaints
No
Risk factors
(AIDS, lower nadir CD4 cell count,
CD4 <200cel/mm3, HAART
interruption, <50years, low school
level, CRF)
No
Yes
Normal
Neurocognitive 
screening
Abnormal Yes
6 months
LP: Lumbar punction
(LP is recommended)
Figure 1 Algorithm for the detection and evaluation of HAND.
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[48,49]. Detection of HIV RNA concentration in the
CSF can also be determined. The presence of HIV RNA
in CSF, even at high concentrations, is not diagnostic
for HAND and cognitively asymptomatic subjects may
have high Viral Load (VL). In the CHARTER study, pa-
tients with CSF VL < 2.5 copies/mL had a higher degree
of neurocognitive impairment compared to the ones
with a VL of 2.5-40 copies/mL [50]. Some studies have
shown slight hyper-proteinorraquia and pleocitosis with
increased mononuclear counts [51]. This increased cel-
lularity has been positively correlated with HIV viral
load in CSF and can be reversed with proper antiretro-
viral treatment. However, these changes can also be
found in subjects without cognitive impairment, so are
not specific for diagnosis of HAND. In HIV infected pa-
tients, different biomarkers have been tested for their
effectiveness, including amyloid peptide B, Tau and
phospho-Tau [52]. HIV population studies show con-
flicting results. Some authors confirm that CSF abnormal-
ities in HIV patients with HAD are similar to those from
Alzheimer’s disease patients (increased tau and phospho-
tau and decreased beta-amyloid peptide) [53] but still
others do not support the idea [54]. A recent study,however, by Steinbrink et al., found a positive correlation
between tau levels and the degree of HAND [55].
The existence of reliable biomarkers would help to diag-
nose patients and would allow better understanding of the
pathophysiology of cognitive impairment in HIV patients,
as well as designing therapeutic strategies aimed at treat-
ing complications. Although there are no pathognomonic
neuroimaging alterations in HAND, it is pertinent to rec-
ommend neuroimaging for investigating other neuro-
logical disorders (opportunistic infections, tumours and
other structural lesions or ischemia/infarction). RM is rec-
ommended and it is preferred to TAC because of its sensi-
tivity [47]. Other techniques are being investigated to
improve the diagnosis of HAND such as cerebral volume-
try, PET, MRI and spectroscopy. They all are able to iden-
tify structural, metabolic and functional disorders which
are related to the presence of cognitive disorder.
Treatment
Since the main cause of cognitive impairment in HIV-
infected patients is the virus infection itself, the treatment
of choice (accepted treatment strategy) remains the use of
HAART defined as a combination of three or more drugs.
Clear improvement in neurological outcomes in the era of
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duction of HAD. However, HAART benefits for HIV cog-
nitive disorders differ substantially between individuals
[56] and several studies have shown in recent years the
persistence of asymptomatic or mild/moderate forms of
HAND [57] leading to speculations that systemically ef-
fective HAART might fail to control CNS-HIV infection,
and also that the type of antiretroviral drug and its pene-
tration may have a role in the development of HAND.
CSF HIV RNA is generally lower than in plasma and nor-
mally decays in parallel to plasma viral load when HAART
is initiated. Therefore, the majority of patients with un-
detectable plasma VL have also undetectable CSF VL.
However, in some cases CSF decay is delayed in response
to HAART and approximately 10% of patients treated with
HAART (for at least 6 months) have VL detectable in LCR
despite suppression of plasma human HIV RNA [58]. It has
been demonstrated that a greater viral suppression within
the CNS is associated with a better neurocognitive function
[59] and may influence survival [60]. Eden et al., found that
patients with neurological disease had a significantly higher
CSF viral load both at baseline and at follow-up compared
with neurologically asymptomatic patients [61].
There is a considerable heterogeneity among different
ARV agents with respect to their CNS penetration. A num-
ber of drug characteristics influence penetration across the
BBB. The latter is composed of a complex of endothelial
cells, transport proteins and basement membrane with fen-
estrated capillaries that together prevent passage of drugs
and other substances into the brain and have the capacity
to express molecular drug pumps or transports such as P-
glycoprotein that can limit the amount of drug that passes
into the brain. Letendre et al., created a CNS penetration
effectiveness ranking system of different ARV agents based
on chemical properties of the drugs (molecular weight,
liposolubility, ion charge and its union with plasma pro-
teins), data on CSF concentrations, and HAART effect-
iveness [62]. It was demonstrated that combination
antiretroviral treatments with higher CNS penetration-
effectiveness (CPE) achieved better CSF viral suppres-
sion [63] and could be associated with better cognition.
There are no conclusive studies on the efficacy of HAART
regimens regarding improvement of cognitive perform-
ance or which is the best combination to prevent or re-
duce cognitive impairment. In general, antiretroviral drugs
have low molecular weight that favors crossing the BBB.
The nucleoside analogue reverse transcriptase inhibitors
(nRTIs) have a low molecular weight, followed by non nu-
cleoside reverse transcriptase inhibitors (NNRTIs). The
protease inhibitors (IPs) have clearly higher molecular
weights and therefore show a low BBB penetration. In
addition, their high affinity for P-glycoprotein makes it dif-
ficult to achieve high concentrations in the CNS. Ritonavir,
a potent inhibitor of P-gp, improves CNS levels of otherPIs when used as a booster [64]. Drugs with less affinity
for P-gp penetrate the CNS more easily. PIs and NNRTIs
exhibit greater fat solubility than nRTIs. Recently, new
ARVs drugs have been approved and are also used in com-
bination with other antiretroviral agents for treating HIV
adult patients: Raltegravir, an integrase inhibitor which
prevents viral DNA insertion into the human cell genome
and Maraviroc, an antagonist of the CCR5 chemokine re-
ceptor, which also serves as an HIV-1 co-receptor. They
have a lower plasma protein binding level than other ARVs
and seem to be a substrate of P-gp transporter. Enfuvirtide
is a fusion inhibitor which is indicated for HIV patients
who have failed prior ART regimens. There are limited data
on the CNS pharmacokinetics of this inhibitor. Finally,
treatment regimens should be designed to optimize CNS
penetration without sacrificing viral suppression or im-
munological improvement. Therefore a treatment regimen
with good CNS penetration could be critical in the case of
patients with disorders associated with neurocognitive
function [65].
Other pharmacological treatments
Despite the introduction of HAART, the persistence of
HAND has led to development of new strategy adjuvants
to HAART. Multiple drugs with neuroprotective properties
have been evaluated. Minocycline, a tetracyclin with neuro-
protective properties and good penetration through the
BBB is being evaluated as a possible adjunct to HAART.
However, clinical trials performed on a cohort of 107 indi-
viduals have not demonstrated improvement in cognitive
function [66]. Memantine, a non-competitive antagonist of
N-methyl-D-aspartate, approved for treatment of Alzhei-
mer’s disease has also been tested in a randomized double-
blind, placebo-controlled, multicenter trial within the Adult
AIDS Clinical Trials Group. No significant improvement in
patients with mild to severe cognitive impairment after
16 weeks of treatment was noted. However, the magnetic
resonance spectroscopy data suggested that memantine
may ameliorate neuronal metabolism, an important step to
stabilizing or preventing neuronal injury [67]. Other drugs
have been investigated, including lithium, selegiline and val-
proate. At the present time, there is no data supporting the
use of any adjuvant therapy to HAART for the treatment of
neurocognitive disorders associated with HIV infection al-
though some drugs such as memantine have been shown
to improve markers of neuronal damage and inflammation
within the CNS.
Non pharmacologic interventions
There is a little information regarding pharmacological in-
terventions in HIV populations which can be extrapolated
to the general population. It is essential to modify lifestyle
(diet, physical activity, stress) and to give up tobacco and al-
cohol. Currently, we can prevent cardiovascular risk factors
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central issue in HIV patients in order to keep control of
VL. Neurocognitive impairment is strongly related to poor
adherence [68]. The later can lead to drug resistance, in-
crease morbidity/mortality and development of cognitive
impairment, especially in the elderly [69]. Neuropyschologi-
cal intervention programs proved to be useful in multiple
pathologies like schizophrenia, acquired brain injury or Alz-
heimer’s disease. However, few studies had been performed
in the HIV field. Some of the programs showed some posi-
tive effects [70] although proper studies with new strategies
presently do not exist.
Prognosis
Before the introduction of HAART, HIV associated neuro-
cognitive impairment was considered a significant inde-
pendent risk factor for AIDS related death. Although the
median survival of patients with HAD has decreased con-
sierably [71] it remains a negative prognostic factor associ-
ated with mortality [25,72]. Other studies have shown that
mild cognitive impairment is also associated with poorer
adherence to treatment [73], higher rates of virological
failure [74], difficulties in the development of everyday
function [75], los of employment [76], impairments in the
quality of life [77] and progression to dementia [78]. In
the post-HAART era, the course of dementia progression
has become more heterogeneous and appears to be related
to factors such as antiretroviral therapy adherence, aging,
substance abuse and psychosocial factors. Evolution is un-
known in patients who have cognitive impairment. Few
studies have been conducted to assess the incidence and
persistence of HAND despite HAART. A study of cohorts
which evaluated a group of 94 patients with HIV-related
neurocognitive impairment, found that to 63% of them,
had persistent neurocognitive deficits within 63 months of
successful treatment. Also, 37% had permanent deficits
without alterations in subsequent visits. They concluded
that the severity of neurocognitive impairment at HAART
initiation seems to be the strongest predictor of persistent
neuropsychological deficits [26]. In another cohort of 1561
HIV+ patients the presence of HAND was associated with
a 3-fold increase in mortality [79].
In recent years the concept of “brain reserve” (CR) has
emerged to describe some individuals having an increased
“baseline adaptive neuroplasticity”, providing greater dy-
namic capacity for adjusting and remodeling cortical cir-
cuits to various stressors [80]. Another neuropsychiatric
symptom that results from CNS viral damage is apathy is
significantly associated with cognitive impairment in indi-
viduals with HIV; Previous literature has demonstrated
CR’s capacity to protect against cognitive decline and ap-
athy in individuals in HIV-infected individuals across the
age span, particularly after a certain threshold of disease
severity [81].Conclusions
Currently, neuropsychological impairment among HIV+
patients on ARV therapy leads to a reduction in the qual-
ity of life and it is an important challenge due to the high
prevalence of HAND and its concomitant consequences
in relation to morbidity and mortality- including those
HIV+ patients with adequate immunological and viro-
logical status. The fact that the virus is established in CNS
in the early stages and its persistence within the CNS can
help us to understand HIV-related brain injury even when
HAART is effective. Longitudinal studies focussing on
neuropsychological function are needed, as there is a
few data on progression and clinical significance of ANI in
these patients. In addition, we have little information
about risk factors or markers of progression of HAND.
The most important risk factors associated with neuro-
cognitive impairment have been described in cross-
sectional studies or non-representative sample, and very
often with contradictory results. It is essential to ad-
dress comorbidities in patients with cardiovascular risk
factors or depression. The rising interest in HIV associ-
ated neurocognitive disorders has led to development
new diagnostic tools, improvement of the neuropsycho-
logical tests, and the use of new biomarkers and new
neuroimaging techniques that can help the diagnosis.
Standardization and homogenization of neurocognitive
tests as well as normalizing and simplification of easily
accessible tools to screen for patients with increased
risk of cognitive impairment and prioritize full neuro-
cognitive study is an urgent requirement. The short
screening instruments would be more important in
places where it is not possible to complete full study.
For the moment, there is not a universal recommenda-
tion how to proceed in clinical practise. It is strongly
recommended to ask patients routinely for cognitive
symptoms as detection of neurocognitive impairment
can justify starting ARV therapy. It is also important to
make a correct monitoring of cognitive complaints on
every visit.
Finally, standard treatment for HIV-associated neuro-
cognitive disorders is an optimal antiretroviral treatment
regimen, along with control and treatment of other
comorbidities or psychiatric problems. For naïve HIV+
patients with evidence of cognitive deficits, it is recom-
mended to start ART with an optimized central nervous
system penetration effectiveness rank. However, pharma-
codynamic studies of HAART are needed in order to de-
termine which drugs can be more effective in preserving
cognitive functioning and when it is necessary to change
the treatment if cognitive impairment appears, even
when virological control has been achieved. Future ef-
forts should also focus on diagnostic keys and searching
for useful strategies in order to decrease HIV neurotox-
icity within the CNS.
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